IP-6

Interactions of phytate and myo-inositol phosphate esters (IP1-5) including IP5 isomers with dietary protein and iron and inhibition of pepsin.

1. J Anim Sci. 2012 Jun;90(6):1824-32. doi: 10.2527/jas.2011-3866. Epub 2012 Jan 6. Interactions of phytate and myo-inositol phosphate esters (IP1-5) including IP5 isomers with dietary protein and iron and inhibition of pepsin. Yu S(1), Cowieson A, Gilbert C, Plumstead P, Dalsgaard S. Author inf

Outpatient management of intussusception: a systematic review and meta-analysis.

1. J Pediatr Surg. 2019 Jul;54(7):1316-1323. doi: 10.1016/j.jpedsurg.2018.09.019. Epub 2018 Oct 22. Outpatient management of intussusception: a systematic review and meta-analysis. Litz CN(1), Amankwah EK(2), Polo RL(3), Sakmar KA(3), Danielson PD(4), Chandler NM(4). Author information: (1)Division of Pediatric Surgery, Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA. Electronic address: clitz@health.usf.edu. (2)Clinical and Translational Research Organization, Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA. (3)Shimberg Health Sciences Library, University of South Florida, Tampa, FL, USA. (4)Division of Pediatric Surgery, Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA. BACKGROUND: Variability in management of intussusception after enema reduction exists. Historically, inpatient observation was recommended; however, there is a lack of evidence-based guidelines for this practice. METHODS: A systematic review and meta-analysis evaluating outcomes between inpatient (IP) and outpatient (OP) management after enema reduction was performed. The following databases were searched: PubMed, EBSCOhost CINAHL, EMBASE, Web of Science, and Cochrane Database. Data from an institutional review were included in the meta-analysis. RESULTS: Ten studies of patients aged 0-18 years with intussusception who underwent successful enema reduction that reported outcomes of outpatient management were included. Overall recurrence rates were 6% for IP and 8% for OP (p = 0.20). Recurrences within 24 (IP: 1% vs OP: 0%, p = 0.90) and 48 h (IP: 1% vs OP: 2%, p = 0.11) were similar. There was no significant difference in the rate of return to the emergency department (IP: 6% vs OP: 14%, p = 0.11). Both groups had a similar rate of requiring an operation (IP: 2% vs OP: 1%, p = 0.84). CONCLUSIONS: Outpatient management of intussusception after enema reduction results in a shorter hospital stay with no difference in the rate of return to the emergency department, recurrence, need for operation, or mortality. The findings of the meta-analysis suggest that outpatient management may be safe and could reduce hospital resource utilization. TYPE OF STUDY: Treatment study. LEVEL OF EVIDENCE: III. Copyright © 2018 Elsevier Inc. All rights reserved. DOI: 10.1016/j.jpedsurg.2018.09.019 PMID: 30503194 [Indexed for MEDLINE]

Effectiveness of an Immersive Telemedicine Platform for Delivering Diabetes Medical Group Visits for African American, Black and Hispanic, or Latina Women With Uncontrolled Diabetes: The Women in Control 2.0 Noninferiority Randomized Clinical Trial.

2. J Med Internet Res. 2023 May 10;25:e43669. doi: 10.2196/43669. Effectiveness of an Immersive Telemedicine Platform for Delivering Diabetes Medical Group Visits for African American, Black and Hispanic, or Latina Women With Uncontrolled Diabetes: The Women in Control 2.0 Noninferiority Randomized Clinical Trial. Mitchell SE(1)(2)(3), Bragg A(3), De La Cruz BA(2), Winter MR(4), Reichert MJ(5), Laird LD(3), Moldovan IA(2), Parker KN(2), Martin-Howard J(3), Gardiner P(1). Author information: (1)Department of Family Medicine and Community Health, University of Massachusetts Chan Medical School, Worcester, MA, United States. (2)Department of Family Medicine, Boston Medical Center, Boston, MA, United States. (3)Department of Family Medicine, Boston University School of Medicine, Boston, MA, United States. (4)Biostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health, Boston, MA, United States. (5)Weatherhead Center for International Affairs, Harvard University, Cambridge, MA, United States. BACKGROUND: Medically underserved people with type 2 diabetes mellitus face limited access to group-based diabetes care, placing them at risk for poor disease control and complications. Immersive technology and telemedicine solutions could bridge this gap. OBJECTIVE: The purpose of this study was to compare the effectiveness of diabetes medical group visits (DMGVs) delivered in an immersive telemedicine platform versus an in-person (IP) setting and establish the noninferiority of the technology-enabled approach for changes in hemoglobin A1c (HbA1c) and physical activity (measured in metabolic equivalent of task [MET]) at 6 months. METHODS: This study is a noninferiority randomized controlled trial conducted from February 2017 to December 2019 at an urban safety net health system and community health center. We enrolled adult women (aged ≥18 years) who self-reported African American or Black race or Hispanic or Latina ethnicity and had type 2 diabetes mellitus and HbA1c ≥8%. Participants attended 8 weekly DMGVs, which included diabetes self-management education, peer support, and clinician counseling using a culturally adapted curriculum in English or Spanish. In-person participants convened in clinical settings, while virtual world (VW) participants met remotely via an avatar-driven, 3D VW linked to video teleconferencing. Follow-up occurred 6 months post enrollment. Primary outcomes were mean changes in HbA1c and physical activity at 6 months, with noninferiority margins of 0.7% and 12 MET-hours, respectively. Secondary outcomes included changes in diabetes distress and depressive symptoms. RESULTS: Of 309 female participants (mean age 55, SD 10.6 years; n=195, 63% African American or Black; n=105, 34% Hispanic or Latina; n=151 IP; and n=158 in VW), 207 (67%) met per-protocol criteria. In the intention-to-treat analysis, we confirmed noninferiority for primary outcomes. We found similar improvements in mean HbA1c by group at 6 months (IP: -0.8%, SD 1.9%; VW: -0.5%, SD 1.8%; mean difference 0.3, 97.5% CI -∞ to 0.3; P<.001). However, there were no detectable improvements in physical activity (IP: -6.5, SD 43.6; VW: -9.6, SD 44.8 MET-hours; mean difference -3.1, 97.5% CI -6.9 to ∞; P=.02). The proportion of participants with significant diabetes distress and depressive symptoms at 6 months decreased in both groups. CONCLUSIONS: In this noninferiority randomized controlled trial, immersive telemedicine was a noninferior platform for delivering diabetes care, eliciting comparable glycemic control improvement, and enhancing patient engagement, compared to IP DMGVs. TRIAL REGISTRATION: ClinicalTrials.gov NCT02726425; https://clinicaltrials.gov/ct2/show/NCT02726425. ©Suzanne E Mitchell, Alexa Bragg, Barbara A De La Cruz, Michael R Winter, Matthew J Reichert, Lance D Laird, Ioana A Moldovan, Kimberly N Parker, Jessica Martin-Howard, Paula Gardiner. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 10.05.2023. DOI: 10.2196/43669 PMCID: PMC10209787 PMID: 37163341 [Indexed for MEDLINE] Conflict of interest statement: Conflicts of Interest: SEM is a consultant on health communication and relationship-centered care and has provided workshops and lectures on this topic funded by pharmaceutical and other industry sponsors. No product endorsement is permitted during these programs. SEM also holds equity in See Yourself Health LLC, a digital health service provider.

Effect of increasing dose level of a novel consensus bacterial 6-phytase variant on phytate degradation in broilers fed diets containing varied phytate levels.

3. Br Poult Sci. 2022 Jun;63(3):395-405. doi: 10.1080/00071668.2021.2000586. Epub 2022 Jan 19. Effect of increasing dose level of a novel consensus bacterial 6-phytase variant on phytate degradation in broilers fed diets containing varied phytate levels. Dersjant-Li Y(1), Christensen T(2), Knudsen S(2), Bello A(1), Toghyani M(3), Liu SY(3), Selle PH(3), Marchal L(1)(4). Author information: (1)Danisco Animal Nutrition, IFF, Oegstgeest, The Netherlands. (2)Danisco Animal Nutrition, IFF, Brabrand, Denmark. (3)School of Life and Environmental Sciences, Faculty of Science, The University of Sydney, Sydney, Australia. (4)Animal Nutrition Group, Wageningen University & Research, Wageningen, The Netherlands. 1. The effect of increasing the dose level of a novel consensus bacterial 6-phytase variant on apparent ileal digestibility (AID) of phosphorus (P), phytic acid (inositol hexa-phosphate, IP6) and ileal IP6 degradation profile was studied in diets containing varying phytate-P (PP) levels.2. Ross 308, one-day-old males (n = 1,800) were allocated to cages (20 birds/cage, six cages/treatment) in a completely randomised design employing a 3 × 5 factorial arrangement (three PP levels: 2.45 (low) 2.95 (medium) and 3.45 g/kg (high); five dose levels of phytase (PhyG): 0, 500, 1,000, 2,000 and 4,000 FTU/kg). Phased diets were based on wheat, corn, soybean meal, rapeseed meal and rice bran (d 0 to 10; 2.60 g/kg digestible P, 7.6 g/kg calcium (Ca); d 11 to 21; 2.10 g/kg digestible P, 6.4 g/kg Ca). Ileal digesta was collected on d 21 for determination of P, IP6 and IP-esters content. Data were analysed by factorial ANOVA; means separation was achieved using Tukey's HSD test.3. Increasing PP reduced AID of IP6 and sum of IP3-6 (%) (P < 0.05) but absolute P-release (g/kg diet) above NC was increased (P < 0.05) at high vs. low PP. Increasing phytase dose exponentially increased (P < 0.001) AID IP6, sum of IP3-6 (%) and digestible IP3-6-P g/kg diet (P < 0.001). AID P was increased but there was an interaction with PP level (P < 0.001). Ileal accumulation of IP5-3-P was universally low with PhyG at ≥1,000 FTU/kg (<0.06 g/100 g DM). At 2,000 and 4,000 FTU/kg, AID IP6 was 97.2, 92.7, 92.6% and 100, 97.2, 97.1%, respectively, at low, medium and high PP. At 2,000 FTU/kg, phytate-P release estimated as the increase (above NC) in ileal digestible sum of IP3-6-P in the diet was 2.26, 2.59 and 3.10 g/kg in low, medium and high PP, respectively.4. The data demonstrated that the novel phytase was effective in breaking down phytate to low IP-esters in diets with varied PP content but the optimal dose level for maximising P-release may differ in diets with varying PP content. DOI: 10.1080/00071668.2021.2000586 PMID: 34739328 [Indexed for MEDLINE]

Effect of Inositol Hexaphosphate (IP(6)) on Serum Uric Acid in Hyperuricemic Subjects: a Randomized, Double-Blind, Placebo-Controlled, Crossover Study.

4. Plant Foods Hum Nutr. 2019 Sep;74(3):316-321. doi: 10.1007/s11130-019-00735-9. Effect of Inositol Hexaphosphate (IP(6)) on Serum Uric Acid in Hyperuricemic Subjects: a Randomized, Double-Blind, Placebo-Controlled, Crossover Study. Ikenaga T(1), Kakumoto K(2), Kohda N(3), Yamamoto T(4). Author information: (1)Otsu Nutraceuticals Research Institute, Nutraceuticals Division, Otsuka Pharmaceutical Co., Ltd., 3-31-13 Saigawa, Otsu, Shiga, 520-0002, Japan. Ikenaga.Takeshi@otsuka.jp. (2)Tokushima Research Institute, Pharmaceuticals Division, Otsuka Pharmaceutical Co., Ltd., 463-10 Kagasuno, Kawauchi-cho, Tokushima, 771-0192, Japan. (3)Otsu Nutraceuticals Research Institute, Nutraceuticals Division, Otsuka Pharmaceutical Co., Ltd., 3-31-13 Saigawa, Otsu, Shiga, 520-0002, Japan. (4)Health Evaluation Center, Osaka Gyoumeikan Hospital, 5-4-8 Nishikujo, Konohana-ku, Osaka, 554-0012, Japan. Inositol hexaphosphate (IP6), a food constituent with various health benefits, has been shown to suppress postprandial elevations of serum uric acid (SUA) levels in healthy adults by inhibiting purine nucleoside and base absorption. Here, we investigated the effect of repeated intake of IP6 on fasting SUA levels in hyperuricemic subjects. This randomized double-blind placebo-controlled crossover design study included 31 asymptomatic hyperuricemic subjects (fasting SUA level > 7.0 but <9.0 mg/dL). Subjects ingested placebo or IP6 drinks (600 mg twice daily) during two 2-week intervention periods with a 2-week washout period. The primary outcome was fasting SUA level; the secondary outcome was the urinary uric acid to creatinine ratio. Fasting SUA levels in the IP6 group were lower than those in the placebo group (p < 0.05). The urinary uric acid to creatinine ratio did not change between the placebo and IP6 groups (p > 0.05). This study showed that a 2-weeks supplementation period of 600 mg IP6 twice daily can improve fasting SUA levels in hyperuricemic subjects. DOI: 10.1007/s11130-019-00735-9 PMID: 31119466 [Indexed for MEDLINE]